Table 2. Baseline clinical characteristics according to ficolin-3 levels (median, IQ range, or n (%)).
| Variable | Hungarian cohort | Norwegian cohort | |||
| Ficolin-3 levels, µg/ml, | <15.0 ug/ml, n = 75 | > = 15.0 µg/ml, n = 115 | <15.0 mg/L, n = 75 | > = 15.0 n = 108 | |
| Age | 72 (62–78) | 67 (58–76) | 59 (47–64) | 58 (51–64) | |
| Male (%) | 51 (68) | 89 (77) | 58 (78) | 85 (79) | |
| Cause of CHF: CAD/IDCM/other | 44/19/12 (59/25/16) | 64/22/29 (56/19/25) | 33/37/4 (45/50/5) | 43/59/4 (41/56/4) | |
| NYHA Class I/II/III/IV | 7/23/31/14 (9/31/41/19)** | 32/38/37/8 (28/33/32/7) | 0/13/33/27 (0/18/45/37)* | 0/38/46/22 (0/36/43/21) | |
| Hypertension (%) | 45 (60)* | 85 (74) | 9 (12) | 18 (16) | |
| T2DM (%) | 24 (32) | 48 (42) | 7 (9) | 15 (14) | |
| Previous infarction (%) | 31 (41) | 45 (39) | 25 (34) | 37 (34) | |
| LVEF (%) | 31 (23–35)*** | 38 (30–41) | 27 (20–36) | 30 (22–40) | |
| ACE-I or ARB (%) | 50 (67) | 79 (69) | 65 (87) | 90 (83) | |
| Beta blocker (%) | 50 (67) | 77 (67) | 63 (85) | 83 (77) | |
| Loop diuretics (%) | 58 (77) | 83 (72) | 58 (78) | 72 (67) | |
| Statins (%) | 27 (36) | 48 (42) | 36 (49) | 43 (40) | |
| Warfarin (%) | 35 (47) | 40 (35) | 41 (55)* | 40 (37) | |
| ASA (%) | 24 (32) | 48 (42) | 26 (35) | 52 (48) | |
| BMI (kg/m2) | 25.4 (23.7–27.9)*** | 28.8 (25.0–32.1 | 24.4 (22.4–27.6)*** | 27.0 (24.7–31.2) | |
| Creatinine (µM/L) | 99 (84–145) | 94 (78–118) | 99 (83–121)** | 84 (71–106) | |
| CRP | 6.4 (2.8–15.9) | 6.2 (3.1–12.4) | 4.3 (2.2–12.0)* | 3.2 (1.4–5.6) | |
| NT-proBNP (pM/L) | 2351 (794–3081)*** | 730 (298–883) | 376 (218–756)*** | 142 (48–339) | |
| Total cholesterol mmol/L | 3.7 (3.0–4.3) *** | 4.4 (3.9–5.2) | 3.8 (3.0–4.6)*** | 4.4 (3.5–5.2) | |
| ASAT (U/L) | 27 (19–34) | 22 (19–31) | 26 (22–32) | 27 (22–34) | |
| ALAT (U/L) | 23 (16–38) | 23 (17–36) | 24 (18–36) | 25 (20–39) | |
| Hemoglobin (g/L) | 141 (124–154) | 142 (131–152) | 134 (121–149)* | 144 (133–150) | |
| Complement C3 (g/L) | 1.08 (0.93–1.25)*** | 1.29 (1.15–1.46) | 1.11 (0.95–1.26)*** | 1.27 (1.12–1.50) | |
| Anaphylatoxin C3a | 268.5 (198.7–382.1) | 208.8 (120.5–339.3) | n.d. | n.d. | |
*
p<0.050.
**
p<0.010.
***
p<0.001;
n.d.: not done.
CAD: coronary artery disease; IDCM: idiopathic dilative cardiomyopathy; NYHA: New York Heart Association; T2DM: Type-2 diabetes mellitus; LVEF: Left-ventricular ejection fraction; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; ACE-I: angiotensin converting enzyme inhibitor; ASA: Acetyl-salicylic acid; ASAT: aspartate aminotransferase; ALAT: alanin aminotransferase.